tetano
Editor, Senior Moderator
Nano Res
. 2022 Jan 28;1-10.
doi: 10.1007/s12274-021-4011-x. Online ahead of print.
Bioengineered pseudovirus nanoparticles displaying the HA1 antigens of influenza viruses for enhanced immunogenicity
Ming Xia[SUP] #[/SUP][SUP] 1 [/SUP], Md Rejaul Hoq[SUP] #[/SUP][SUP] 2 [/SUP], Pengwei Huang[SUP] #[/SUP][SUP] 1 [/SUP], Wen Jiang[SUP] 2 [/SUP], Xi Jiang[SUP] 1 3 [/SUP], Ming Tan[SUP] 1 3 [/SUP]
Affiliations
Abstract
Even with implementation of current influenza vaccines, influenza still claims up to 500,000 lives worldwide annually, indicating a need for a better vaccine strategy. We have developed a technology to generate unique S[SUB]60[/SUB]-HA1 pseudovirus nanoparticles (PVNPs) that display the receptor-binding HA1 domains of influenza viruses. Each self-assembled S[SUB]60[/SUB]-HA1 PVNP consists of a T = 1 icosahedral S[SUB]60[/SUB] nanoparticle that resembles the inner shell of norovirus capsid and 60 surface-displayed HA1 antigens that are excellent vaccine targets. Soluble S[SUB]60[/SUB]-HA1 PVNPs presenting HA1 antigens of H7N9 influenza virus subtypes have been produced efficiently in large amount. Their three-dimensional (3D) structures have been solved by cryogenic electron microscopy. The PVNP-displayed HA1 antigens react with HA-specific antibody, and retain authentic sialic acid binding specificity and hemagglutinate human erythrocytes. The PVNPs are highly immunogenic, eliciting high titers of HA1-specific antibodies in mice and the mouse sera strongly inhibited hemagglutinations of homologous and heterologous influenza virus HA proteins. Therefore, the S[SUB]60[/SUB]-HA1 PVNPs may provide useful reagents to study influenza viruses and offer a potential new vaccine tactic to fight the deadly influenza disease.
Keywords: S60 nanoparticle; hemagglutinin; influenza vaccine; influenza virus; norovirus; pseudovirus nanoparticle.
. 2022 Jan 28;1-10.
doi: 10.1007/s12274-021-4011-x. Online ahead of print.
Bioengineered pseudovirus nanoparticles displaying the HA1 antigens of influenza viruses for enhanced immunogenicity
Ming Xia[SUP] #[/SUP][SUP] 1 [/SUP], Md Rejaul Hoq[SUP] #[/SUP][SUP] 2 [/SUP], Pengwei Huang[SUP] #[/SUP][SUP] 1 [/SUP], Wen Jiang[SUP] 2 [/SUP], Xi Jiang[SUP] 1 3 [/SUP], Ming Tan[SUP] 1 3 [/SUP]
Affiliations
- PMID: 35106126
- PMCID: PMC8795936
- DOI: 10.1007/s12274-021-4011-x
Abstract
Even with implementation of current influenza vaccines, influenza still claims up to 500,000 lives worldwide annually, indicating a need for a better vaccine strategy. We have developed a technology to generate unique S[SUB]60[/SUB]-HA1 pseudovirus nanoparticles (PVNPs) that display the receptor-binding HA1 domains of influenza viruses. Each self-assembled S[SUB]60[/SUB]-HA1 PVNP consists of a T = 1 icosahedral S[SUB]60[/SUB] nanoparticle that resembles the inner shell of norovirus capsid and 60 surface-displayed HA1 antigens that are excellent vaccine targets. Soluble S[SUB]60[/SUB]-HA1 PVNPs presenting HA1 antigens of H7N9 influenza virus subtypes have been produced efficiently in large amount. Their three-dimensional (3D) structures have been solved by cryogenic electron microscopy. The PVNP-displayed HA1 antigens react with HA-specific antibody, and retain authentic sialic acid binding specificity and hemagglutinate human erythrocytes. The PVNPs are highly immunogenic, eliciting high titers of HA1-specific antibodies in mice and the mouse sera strongly inhibited hemagglutinations of homologous and heterologous influenza virus HA proteins. Therefore, the S[SUB]60[/SUB]-HA1 PVNPs may provide useful reagents to study influenza viruses and offer a potential new vaccine tactic to fight the deadly influenza disease.
Keywords: S60 nanoparticle; hemagglutinin; influenza vaccine; influenza virus; norovirus; pseudovirus nanoparticle.